Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Difficult-to-Treat Rheumatoid Arthritis
NCT07315503Phase 1Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2027
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GC012 in rheumatoid arthritis (RA) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity Rate at 28 days and Adverse Events, Serious Adverse Events, Adverse Event of Special Interest Rate at 15 years. Planned start Dec 2027; status: withdrawn.
02
Drugs
GC012
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07315503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315503.